N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine | 1350913-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine
• 英文别名: N-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine
• CAS: 1350913-08-4
• 化学式: C₁₂H₁₉BN₂O₂
• 分子量: 234.106
• InChiKey: XHSDOOFCOGZVOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.42
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  43.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 在 potassium phosphate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 (2-dicyclohexylphosphino-2’,6’-diisopropoxy-1,1‘-biphenyl)[2-(2’-methylamino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 potassium carbonate 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 8.0h， 生成 3-(Fluoromethyl)-1-[2-[2-(methylamino)pyridin-4-yl]quinolin-6-yl]azetidin-3-ol
  参考文献：
  名称：

  N -METHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE COMPOUNDS

  摘要：

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3are as defined in the specification. The compounds may be radiolabeled compounds and are useful for diagnostic imaging using positron emission tomography (PET). The compounds of the present disclosure may be used, for example, in diagnostic imaging of 4R tau aggregates.

  公开号：

  WO2024049976A1
• 作为产物：
  描述：

  联硼酸频那醇酯 、 4-溴-n-甲基吡啶-2-胺 在 (C5H5FeC5H3C(CH3)NC6H4CH3)PdCl(tricyclohexylphosphine) 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 6.0h， 生成 N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine
  参考文献：
  名称：

  通过钯环催化的一锅串联硼酸化/铃木-宫浦交叉偶联反应合成联芳基化合物

  摘要：

  环钯二茂铁亚胺 I 的三环己基膦加合物在低催化剂负载量（2 mol%）的一锅硼化/铃木-宫浦偶联（BSC）反应中表现出高催化活性。对于 37 个实施例，以良好到极好的收率获得了各种联芳基化合物。该方法适用于含有多种官能团的芳基和杂芳基卤化物（Br和Cl），不需要过量的磷烷配体，也不需要在第二步中加入钯催化剂。

  DOI：

  10.1002/ejoc.201101409

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• [EN] COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR<br/>[FR] COMPOSITIONS COMPRENANT UN INHIBITEUR DE PI3K ET UN INHIBITEUR DE HDAC
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2017029514A1

  公开（公告）日：2017-02-23

  The invention relates to a pharmaceutical composition comprising at least one PI3K inhibitor of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor such as a compound of Formula II or a pharmaceutically acceptable salt thereof; or at least one PI3K inhibitor such as a compound of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor of Formula II or a pharmaceutically acceptable salt thereof.

  该发明涉及一种药物组合物，包括至少一种式I的PI3K抑制剂或其药用可接受盐，以及至少一种HDAC抑制剂，例如式II的化合物或其药用可接受盐；或者至少一种PI3K抑制剂，例如式I的化合物或其药用可接受盐，以及至少一种式II的HDAC抑制剂或其药用可接受盐。
• [EN] COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS<br/>[FR] ASSOCIATIONS COMPRENANT DES INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2017208032A1

  公开（公告）日：2017-12-07

  The invention relates to a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of proteasome inhibitors, tumour immunotherapeutics or immunomodulatory agents, signal transduction pathway inhibitors, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.

  该发明涉及公式(I)的化合物或其药用可接受的盐，以及来自蛋白酶体抑制剂、肿瘤免疫治疗剂或免疫调节剂、信号传导途径抑制剂、抑制BCL2蛋白家族的药剂、抑制Mcl-1的药剂、聚(ADP-核糖)聚合酶（PARP）抑制剂、芳香化酶抑制剂、传统细胞毒剂或从阿比特龙、ARN-509和MYC抑制剂中选择的其他药剂中至少一种第二药剂的组合。
• [EN] NOVEL HISTONE DEACETYLASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2014181137A1

  公开（公告）日：2014-11-13

  The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.

  本发明是该化合物的化合物或其药学上可接受的盐。这些化合物可用作HDAC抑制剂。